Allos Therapeutics, Inc., is a biopharmaceutical company that develops drugs for the treatment

of cancer. Allos Therapeutics reported the following financial data (in thousands)

for three recent years:

For Years Ended December 31

Year 3 Year 2 Year 1

Cash and cash equivalents $ 48,402 $141,423 $ 30,696

Net cash flows from operations (63,656) (62,199) (42,850)

a. Determine the monthly cash expenses for Year 3, Year 2, and Year 1. Round to one

decimal place.

b. Determine the ratio of cash to monthly cash expenses for Year 3, Year 2, and Year 1

as of December 31. Round to one decimal place.

c. Based on (a) and (b), comment on Allos Therapeutics ratio of cash to monthly

operating expenses for Year 3, Year 2, and Year 1.